Compare Bumi Resources Minerals Tbk (BRMS) vs Dharma Polimetal Tbk. (DRMA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bumi Resources Minerals Tbk vs Dharma Polimetal Tbk. — how do they compare? Bumi Resources Minerals Tbk trades at Rp555 (market cap 81.53T, 393.8M 24h volume), while Dharma Polimetal Tbk. trades at Rp930 (market cap 4.35T, 825.7K 24h volume). The key difference: Bumi Resources Minerals Tbk is far larger — about 18.7× Dharma Polimetal Tbk.'s market cap, and Bumi Resources Minerals Tbk is more actively traded (393.8M versus 825.7K). Which is the better fit depends on your goals.
| BRMS | DRMA | |
|---|---|---|
Market Cap | 81.53T | 4.35T |
Volume | 393.8M | 825.7K |
Lot | 3.94M | 8.26K |
Turnover | 223.64B | 768.05M |
Average Price | 567.9 | 930.18 |
Value | 223.64B | 768.05M |
Indicative Equilibrium Price | 555 | 930 |
Indicative Equilibrium Volume | 234.77K | 2 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bumi Resources Minerals Tbk
PT Bumi Resources Mineral (the company) was established under its original name of PT Panorama Timur Abadi base on notarial deed No.3 of Mr Safrudin, S.H, dated on 6 Aug, 2003. The Company’s articles of association has been amended several times, most recently by notarial deed No.102 of Humberg Lie, S.H., dated Jun 22, 2010, concerning among others, change the name of the company the composition of the Board of Directors and Commissioners, and public offering.
Read more on BRMS →About Dharma Polimetal Tbk.
PT Dharma Polimetal Tbk (“the Company”) was established in the Republic of Indonesia on 27 March based on Notarial deed No. 74 of Rukmasanti Hardjasatya, S.H. The Company begin opertions on year 1989 and commenced its commercial activities since 1990. The Company’s Majority shareholder is PT Dharma Inti Anugerah, established in Republic Indonesia on 20 November 2003.
Read more on DRMA →
